AG
MRSN

Artal Group’s Mersana Therapeutics MRSN Stock Holding History

Artal Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-121,182
Closed -$9.97M – 113
2023
Q2 		$9.97M Buy
121,182
+32,550
+37% +$4.76M 0.31% 49
2023
Q1 		$9.11M Buy
88,632
+632
+0.7% +$88.7K 0.54% 44
2022
Q4 		$12.9M Hold
88,000
– – 0.72% 36
2022
Q3 		$14.9M Hold
88,000
– – 0.63% 35
2022
Q2 		$10.2M Hold
88,000
– – 0.54% 35
2022
Q1 		$8.78M Buy
88,000
+40,000
+83% +$4.67M 0.37% 54
2021
Q4 		$7.46M Hold
48,000
– – 0.2% 82
2021
Q3 		$11.3M Hold
48,000
– – 0.25% 78
2021
Q2 		$16.3M Hold
48,000
– – 0.33% 65
2021
Q1 		$19.4M Hold
48,000
– – 0.34% 68
2020
Q4 		$31.9M Buy
48,000
+8,000
+20% +$4.45M 0.69% 40
2020
Q3 		$18.6M Buy
40,000
+8,000
+25% +$4.04M 0.45% 48
2020
Q2 		$18.7M Buy
+32,000
New +$10.9M 0.52% 45

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Artal Group's MRSN Position: Q3 2023 in Review

Artal Group sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 121,182 shares — an estimated $9.97M sold.

Artal Group first reported a position in MRSN in Q2 2020 and held it in 13 quarters. The position peaked at $31.9M in Q4 2020. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Artal Group reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Artal Group sold 121,182 Mersana Therapeutics shares in Q3 2023, an estimated $9.97M.
  • Artal Group first reported a position in Mersana Therapeutics in Q2 2020 and held it in 13 quarters.
  • Artal Group's Mersana Therapeutics position peaked at $31.9M in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.